|
|
Widewater Place, Moorhall Road, HarefieldUxbridge
Middlesex, UB9 6NS UK
phone:+44 (0) 1895 826 600
fax:+44 (0) 1895 825 865
|
|
| Symbol |
Private |
| Founded |
1906 |
| Employees |
|
|
|
| www.norgine.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Pharma products: gastroenterology, hepatology, pain management |
|
| Management |
| Peter Stein, Chief Executive Officer |
| |
|
|
| |
|
| Keywords |
| gastroenterology, hepatology, incontinence, chronic constipation, colonoscopy |
|
|
|
| Description |
|
Norgine's focus is pharmaceutical products that address significant unmet clinical need in areas such as gastroenterology, hepatology and pain management. They currently market 8 products in their key therapeutic areas, e.g. MOVICOL for the treatment of chronic constipation and faecal impaction, MOVIPREP for bowel preparation prior to colonoscopy, FIVASA for the treatment of ulcerative colitis and Crohn's Disease and ORAMORPH for the treatment of moderate to severe pain. Norgine has a highly active Research & Development division and currently has more than 10 products at various stages of clinical development in our core areas of gastroenterology and pain management. The company is undertaking a significant clinical development programme both in the USA and Europe with NRL 972, a liver diagnostic. NRL 972 promises to provide a real advance in the diagnosis, staging and treatment of a variety of degenerative liver diseases including Non-Alcoholic Fatty Liver Disease (NAFLD) and Viral Hepatitis to the benefit of patients, their carers and society at large. |
|
| Products / Services |
Norgine's range of gastroenterology products includes therapies for faecal impaction, irritable bowel syndrome, constipation, gastro-oesophageal reflux and inflammatory bowel disease.
|
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members